This Startup is Growing 23X Faster than Nvidia

Claim your stake before the IPO  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

July 01, 2026 Editor’s Note: Former tech executive Jeff Brown picked Bitcoin, Tesla, and Nvidia before they jumped as high as 52,400%, 2,150% and 36,000%. Now he’s recommending an Elon Musk-backed startup that has been called “the fastest-growing business in the history of capitalism.” And you can claim your pre-IPO stake for less than $50. Click here to see the details and get the name of this startup, 100% free… or read more below. Dear Reader, See this document below? Elon Musk just revealed what I believe is the biggest investment opportunity of the year when he filed this official document with the SEC. Because on page 146 he revealed the name of a startup that’s set to be… The next monster IPO on Wall Street. (Click here to get the details.) Even though this has nothing to do with robots, self-driving cars, or rockets… This startup is growing faster than Tesla… Faster than SpaceX… And it’s even growing 23 times faster than Nvidia. That’s why The Atlantic called it… “The fastest-growing business in the history of capitalism.” These types of explosive IPO opportunities are normally off-limits to everyday folks like you. They’re reserved for rich people on Wall Street and Silicon Valley. But I found a way for you to claim your stake before the IPO… starting for less than $50. Click here to see the details, including the name of this startup, completly free of charge.      We have so much to look forward to, Jeff Brown Founder & CEO, Brownstone Research Your Investimonials account is active and this message was sent as part of your current subscription. If you did not request this email or believe it was sent in error, please reply directly so our team can review your account. Account Status and Subscription Details Your subscription is confirmed and your delivery preferences are up to date. You are currently receiving content based on the schedule and frequency you selected during registration. If you need to adjust your delivery window, change your email frequency, or pause updates temporarily, reply to this message and our team will process your request within one business day. Your most recent account activity was logged and no unusual access was detected. If you did not recently sign in or update your preferences, please reply to this email immediately so we can secure your account. We recommend reviewing your login history periodically and updating your password if anything appears unfamiliar. As a subscriber, your current access includes daily market briefings, watchlist alerts, and periodic research digests. These are delivered according to the preferences you set during enrollment. A confirmation of your original registration is available upon request. Billing and Transaction History If you have questions about a recent charge, your renewal date, or your current subscription tier, reply to this email and a member of our billing team will provide your account details. We maintain complete records of all transactions associated with your account and can furnish a full statement upon request. For subscribers with active paid memberships, billing occurs on the renewal date established at the time of purchase. If you need to update your payment method on file, please contact our team directly rather than clicking any links in forwarded emails. We process all payment updates manually to protect against unauthorized changes. If you believe a charge was made in error, please contact us within 30 days of the transaction date. Refund requests are reviewed individually and typically processed within five to seven business days. You will receive a confirmation email once any adjustment has been applied to your account. Please note that we will never ask you to provide full payment card numbers, bank account details, or login credentials via email. Any message requesting this information should be considered fraudulent and reported to our team immediately. Managing Your Communication Preferences We understand that inbox management is personal and we respect your time. You have full control over the types of messages you receive from us. Available options include daily alerts, weekly summaries, breaking market updates only, or a temporary pause on all communications. To update your preferences, reply to this email with your request. Our team handles preference changes manually to ensure accuracy. Changes typically take effect within 24 to 48 hours. If you previously submitted a request and it has not been reflected, please reply again referencing your original message and we will prioritize it. If you prefer to unsubscribe entirely, you may do so using the link provided at the bottom of this email. The process is straightforward and your request will be honored promptly. We do not use misleading tactics to prevent unsubscription and we respect every subscriber's decision. Privacy and Data Handling Your personal information, including the name and email address you provided at registration, is stored securely and accessed only by authorized members of our team. We do not sell, rent, license, or disclose your information to third parties for marketing purposes. Our data handling practices are reviewed regularly to ensure compliance with applicable regulations. We follow industry-standard protocols for data storage and transmission. Subscriber records are maintained only for as long as necessary to fulfill your subscription and any applicable legal obligations. If you would like to request a copy of the personal information we hold on file for you, or if you would like that information deleted, please reply to this email. We will process your request and confirm completion within ten business days. We may update our privacy practices periodically. When changes are made, you will be notified via email with a summary of what has changed. Your continued use of our services following such notification indicates acceptance of the revised terms. Account Security We take the security of your account seriously. All subscriber data is transmitted using encryption and stored on systems that are monitored for unauthorized access. We encourage subscribers to use unique, strong passwords and to be cautious of unsolicited messages requesting personal information. If you receive a suspicious email that appears to be from Investimonials, please forward it to our team for investigation. We will review the message and advise you on whether it is legitimate. Do not click links or download attachments from messages you are unsure about. For added security, we recommend reviewing your account settings periodically to confirm that your contact information and preferences are current. If you notice any discrepancies, reply to this email and our team will assist you. Contacting Support Our support team is available Monday through Friday during standard business hours. We make every effort to respond to all inquiries within one business day. For urgent account security concerns, we prioritize faster response times. To reach our team, reply directly to this email. Please include your full name and the email address associated with your subscription so we can locate your records promptly. If you are writing on behalf of another subscriber, please include their written authorization. We welcome your feedback on our content, communication frequency, and overall subscriber experience. Every response is reviewed and your input directly influences how we improve our service. Content Disclaimer The information provided through Investimonials is intended for educational and informational purposes. Market conditions are subject to rapid change and past performance is not indicative of future results. Subscribers are encouraged to perform their own due diligence and consult with qualified financial professionals before making investment decisions. Our editorial team works to ensure the accuracy of information at the time of publication. However, we cannot guarantee that all information remains current after delivery. If you identify an error in any of our content, please notify us and we will issue a correction promptly. Thank you for being an active Investimonials subscriber. We value your trust and your time. If there is anything we can do to improve your experience, please do not hesitate to reach out by replying to this message.   Update your email preferences or unsubscribe here © 2026 Stable Financial Publications 1013 Centre Road Suite 403-D Wilmington, DE 19805, United States Terms of Service

Stocks Up Again, Nasdaq And S&P Lead, New Record Closes For The Dow, Small-Cap And Mid-Cap Indexes

Today's Market Moves from Zacks  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Stocks Up Again, Nasdaq And S&P Lead, New Record Closes For The Dow, Small-Cap And Mid-Cap Indexes

	Profit from the Pros By Kevin Matras Executive Vice President
	Stocks Up Again, Nasdaq And S&P Lead, New Record Closes For The Dow, Small-Cap And Mid-Cap Indexes Stocks closed higher again yesterday with all of the major indexes in the green. And like the day before, the tech-heavy Nasdaq led the way with an outsized gain of 1.52%, followed by the S&P 500 with 0.79%. And also like the day before, the Dow, small-cap Russell 2000, and mid-cap S&P 400, made new all-time high closes in the process. The day started with a positive statement from Iran where they acknowledged the Memorandum of Understanding (MOU), and said they would abide by it, as long as the U.S. does. Seems like a basic thing to acknowledge, but given some earlier denials, and strikes over the weekend, and suggestions they wouldn't attend the next round of talks in Qatar, it was an important declaration. And Iran did send a delegation to Qatar for the next round of talks. Tech and AI-related names continued their rebound after a bout of volatility last week. Sandisk was up 10.9%. Applied Materials was up 4.08% (and that's after the previous day's 10.8%). And Advanced Micro Devices was up 7.68%. In other news, yesterday's Case-Shiller Home Price Index (unadjusted) was up 1.0% m/m, the same as last month's pace. The y/y change was 1.1%, up from last month's 0.8% and views for 0.9%. The FHFA House Price Index was off -0.1% m/m, but was up 2.0% y/y in comparison to last month's 1.7%, albeit just under the consensus for 2.1%. The Chicago PMI report put the index at 56.7, down from last month's 62.7, but above expectations for 55.4. Consumer Confidence came in at 91.2 vs. last month's 90.6, but under estimates for 94.8. And the Job Openings and Labor Turnover Survey report (or JOLTS for short) showed 7.594 million job openings last month, up from last month's 7.585M, and above the forecast for 7.298M. Today we'll get MBA Mortgage Applications, the PMI Manufacturing Report, the ISM Manufacturing Index, Construction Spending, Weekly Jobless Claims, the Challenger Job-Cut Report, and the ADP Employment Report (the latter of which is often looked at as a barometer of what the Employment Situation report will say a day or two later). Plenty of labor stats today. But the jobs report everybody is really waiting for is Thursday's Employment Situation report by the Bureau of Labor Statistics (BLS). The headline number is expected to show 114,000 new jobs were created in June (124,000 in the private sector and -10,000 in the public sector). That would be a slower pace than May's 172,000 headline, but the private sector would actually be a bit higher than last month's pace of 120K. The unemployment rate is expected to remain unchanged at 4.3%. And average hourly earnings are expected to be up 0.3% m/m (same as last month), while the y/y rate ticks up to 3.5% vs. last month's 3.4%. Today's ADP report could foreshadow what tomorrow's BLS report will say. But the ADP report does have a spotty track of doing so. So all eyes will be on Thursday's BLS report (which comes a day earlier than usual since the market is closed on Friday in observance of July 4th Independence Day). With 2 days left, all of the major indexes are in the plus column for the week so far. If all goes well, they'll stay that way, and even expand that margin even more. See you tomorrow, Kevin Matras Executive Vice President, Zacks Investment Research
	Just Released: 4 Stocks for Biggest Upside in Q3 2026 Four Zacks experts each announce their single favorite stock to gain the most in the next three months: Stock #1: Communications Company Undergoing Major Transformation Stock #2: AI Infrastructure Company that More than Tripled Revenue Stock #3: Materials Firm Set to Soar on AI-Fueled Capex Supercycle Stock #4: Under-the-Radar Chipmaker Primed for Breakout in Red Hot Industry Today, you are invited to download the private Ultimate Four Special Report that names these stocks and spotlights why their gain potential is so immediate and exceptional. See Stocks Now >>
	Today's Top Research New Zacks Strong Buys for July 1st Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today. Read More » Do These Beaten Down Stocks Deserve a Closer Look? NIKE and Lululemon have seen extended periods of poor share performance, but are there opportunities in the weakness? Read More » Applied Materials (AMAT) Hits New All-Time Highs: Still Time to Buy Stock in the AI Chip Equipment Leader? AMAT has been one of the hottest stocks in the tech sector, climbing to fresh all-time highs, and has now rallied nearly 200% year to date. Read More » These 3 Small Cap Stocks Sport Bullish Outlooks GDOT, PRTH, and MO have enjoyed notable strength over recent months, with each also sporting a Zacks Rank #1 (Strong Buy). Read More » Corporate Profits Climb to Fresh Highs: ETFs in Focus Record corporate profits and elevated margins put earnings-focused ETFs like EPS, EZM and EES in the spotlight. Read More »
	Start Every Day Ahead of Wall Street Before you make a trade, get today's market news from Zacks' latest Ahead of Wall Street article. With timely information from Zacks analysts, each daily article features a preview of where the market is headed. Plus, Zacks #1s on the move, stock research reports, earnings and economic news, and a top-headline analyst blog. All of it in one easy-to-follow place to give you the edge. Get the latest news >>
	Best Artificial Intelligence (AI) Stocks to Buy Now June 2026 Investors should consider highly rated stocks HP, DELL and MU to buy now. Read More » Bull of the Day: Quanta Services (PWR) PWR is perfectly positioned to benefit from historic energy demand and the critical infrastructure required to supply it. Read More »
	More Zacks Resources Mobile App Download our app for convenient on-the-go access to even more—daily and weekly newsletters published by Zacks experts, proprietary research and tools, and Portfolio Tracker on Zacks.com.
	Zacks Members' Success Stories Visit Success Stories to hear how Zacks research, tools and portfolios help our members outperform the market.
	To ensure the latest Zacks content arrives in your inbox, follow the quick and easy whitelisting instructions for your specific email provider. And follow us for all of our market insights.
	This free resource is being sent by Zacks.com. We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms of Service". www.zacks.com/terms_of_service Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research is not a licensed securities dealer, broker or U.S. investment adviser or investment bank. The Zacks #1 Rank Performance covers the period beginning on January 1, 1988 through June 1, 2026. The performance is the equal weighted performance of a hypothetical portfolio consisting of stocks with a Zacks Rank of #1 that was rebalanced monthly from January 1988 through December 2013 and weekly from 12/31/13 through Monday's open on June 1, 2026. For each stock with a Zacks Rank #1 at the beginning of the month, the total return during the month was calculated as the % change in the price of the stock from the closing price of the prior month to the closing price of the current month plus any dividends received during the month. The monthly individual stock returns were then averaged to determine the portfolio return for the month. For each stock with a Zacks Rank #1 at the beginning of the week, the total return during the week was calculated as the % change in the price of the stock from the opening price for the week to the opening price of the next week plus any dividends received during the week. The weekly individual stock returns were then averaged to determine the portfolio return for the week. If no month-end price or week end open price was available for a stock, it was not included in the portfolio return for the month or the week. The monthly and weekly returns were compounded to arrive at the annual returns. The annualized return is the annual return that, had it been achieved in each year or portion of a year, would have compounded to create the total return over the full time period. These returns are based on the list of Zacks Rank #1 Stocks that was available to clients of Zacks as of the beginning of the month, when returns were calculated monthly, or as of the beginning of the week when returns were calculated weekly. These returns are higher than the returns an investor could achieve investing real money in a portfolio of Zacks Rank #1 stocks because the returns of the hypothetical Zacks Rank #1 portfolio exclude a number of costs, including commissions incurred for trading, the average bid ask spread, the price impact of the trading and, prior to 2013, in those months when the end of the month fell on Friday, Saturday or Sunday, the overnight return from the month end close to the open on the next trading day. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance_disclosure for information about the performance numbers displayed above. Zacks Emails If you would prefer to not receive future profit-producing emails from Zacks.com the primary purpose of which is the commercial advertisement or promotion of a commercial product or service, then please click here and confirm your request. If you have trouble with the unsubscribe link, please email support@zacks.com. Zacks Investment Research 101 N. Wacker Drive, Floor 15 Chicago, IL 60606

AM Wake Up: (Nasdaq: NCEL) Aims For Disruption In The T1D Market (7 Potential Catalysts)

Were you on watch for Tuesday's breakout idea? It popped in an impressive manner.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored AM Wake Up: (Nasdaq: NCEL) Aims For Disruption In The T1D Market (7 Potential Catalysts) Consider Starting Your Own Research On (NCEL)... [ Company Website ] | [ Corporate Communications ] *Click Here To Get Our Alerts Faster Via SMS* July 1st Dear Reader, Were you on watch for Tuesday's breakout idea? It popped in an impressive manner. Surging to a high of $9.73 before the bell, it moved approx. 110% from its prior day close of $4.62. While that run was unfolding, our attention started getting dragged in another direction... You see, there is a particular kind of company that doesn't announce its arrival loudly. It moves through regulatory checkpoints, builds out its science, assembles the right advisors, and one day finds itself standing at the threshold of a First-In-Human clinical trial, pursuing one of the few genuinely differentiated approaches to treating a disease that has resisted a functional cure for over a century. On May 27th, 2026, this company filed a Pre-IND briefing package with the U.S. FDA to support a proposed First-In-Human trial of its lead stem cell-derived islet product, in combination with tegoprubart, developed by Eledon Pharmaceuticals. Furthermore, a Type B meeting with the FDA was scheduled for the final week of June. NewcelX Ltd. (Nasdaq: NCEL) is the product of a merger finalized on October 30th, 2025, between NLS Pharmaceutics Ltd. and Kadimastem Ltd, a cell therapy company. The deal united Kadimastem's validated human pluripotent stem cell platform with a focus on translational regenerative medicine and cell therapy development across metabolic disease and immune-modulated indications. The combined company relisted on Nasdaq under NCEL. The Underlying Science Deserves Attention Type 1 Diabetes is a condition in which the body's own immune system destroys the insulin-producing beta cells in the pancreas. The approach NewcelX is advancing with NCEL-101 is fundamentally different: replace the destroyed islet cells using scalable, off-the-shelf, stem cell-derived islets, and pair those transplanted cells with targeted immune protection. The collaborative framework with Eledon, specifically tegoprubart, evaluated in over 100 transplant recipients across multiple FDA-cleared IND studies, is what makes the immune protection component clinically credible. The company maintains access to a $25Mn Equity Line of Credit and is substantially debt-free. With a market capitalization hovering around $19Mn (6/30/26), the gap between this company's current chart valuation and the scale of the unmet medical need it is targeting may be one of the more striking disconnects in the clinical-stage biopharma space right now. Two Platforms, One Clinical Mission NewcelX Ltd. (Nasdaq: NCEL) is a clinical-stage regenerative medicine company incorporated in Switzerland and headquartered in Zurich, with research and development operations in Ness Ziona, Israel. The company's operating model is built around an allogeneic, off-the-shelf cell therapy manufacturing strategy Rather than producing patient-specific therapies, NewcelX is designing its pipeline to be manufactured from renewable pluripotent cell banks, frozen, and shipped globally, an approach that supports broad patient access and standardized production at scale. “We believe our scalable stem cell-derived islet platform, combined with targeted immune protection, represents one of the few differentiated approaches aimed at a potential functional cure for Type 1 Diabetes.” — Ronen Twito, Executive Chairman & CEO, NewcelX Ltd. | April 30th, 2026 Cell Therapy for T1D - Structural Scale, Unsolved Problem The global cell therapy market represents one of the most structurally significant long-cycle themes in heal-thcare. Unlike traditional pharmaceuticals that interact with biochemistry, cell therapies aim to replace or restore biological function at the cellular level, an approach that, in diseases like Type 1 Diabetes, offers the possibility of functional resolution rather than lifelong symptom management. Global T1D Patients - 9.5Mn Children with T1D - 1.8Mn U.S. Annual Diabetes Cost - $640Bn / year Curative Standard of Care - None Currently Exists What gives this market context particular strategic weight right now is the regulatory environment. The FDA has publicly signaled a commitment to streamlining the IND process for Type 1 Diabetes innovations, a point referenced directly by CEO Ronen Twito in the company's May 2026 Pre-IND announcement. The combination of scalable stem cell-derived islets with a calcineurin inhibitor-free immune protection regimen represents a small cohort of programs globally. Recent NCEL Milestones May 27th, 2026 - FDA Pre-IND Package Submitted For NCEL-101 NewcelX filed its Pre-IND briefing package with the FDA to support the proposed First-In-Human trial of NCEL-101 combined with tegoprubart. A Type B pre-IND meeting with the FDA was scheduled for the final week of June 2026. Agenda covers manufacturing, preclinical safety/toxicology planning, and FIH trial design. March 9th, 2026 - Strategic Collaboration Announced With Eledon Pharmaceuticals Formal collaborative research agreement to advance combination strategies pairing NCEL-101 with tegoprubart (AT-1501). Designed to support durable, immune-protected islet replacement and a potential functional cure for Type 1 Diabetes. January 5th, 2026 - Dr. Julien Boisdron (CMO of Roche) Appointed To Scientific Advisory Board Diabetes specialist with 20+ years of global pharmaceutical leadership, currently CMO of a major Swiss multinational pharma company, joins the SAB to advise on NCEL-101 translational strategy, patient adoption, and commercialization frameworks. October 31st, 2025 - Merger Completed As NCEL Takes A Spin On The Nasdaq NLS Pharmaceutics x Kadimastem merger closed; combined company relisted as NewcelX Ltd. (NCEL) on the Nasdaq. Consider Starting Your Own Research On (NCEL)... [ Company Website ] | [ Corporate Communications ] These 7 Potential Catalysts Put (Nasdaq: NCEL) At the Top of Our Watchlist #1. FDA Engagement The Type B pre-IND meeting scheduled with the FDA for the last week of June 2026 puts NCEL in direct regulatory dialogue at a moment when the agency has publicly signaled its commitment to streamlining the IND pathway for Type 1 Diabetes cell therapy innovations. #2. Tight Float With approximately 2.61Mn shares in its float, NCEL carries one of the tighter share structures in the clinical-stage biotech space, a factor that becomes relevant when catalysts arrive and market interest accelerates. #3. Validated Science The human pluripotent stem cell platform underpinning the company's NCEL-101 program has been validated through years of GMP manufacturing development, prior FDA interactions, and preclinical work accumulated during the AstroRx® ALS program, all now applied directly to the flagship diabetes asset. #4. Strategic Alliance The collaborative research agreement between NCEL and Eledon Pharmaceuticals integrates tegoprubart, a next-generation anti-CD40L antibody with safety data from over 100 transplant recipients, into the immune protection layer of NCEL-101, meaningfully reducing a core technical risk in islet cell therapy. #5. Off-the-Shelf Model NCEL's allogeneic manufacturing strategy is designed for scalability and cost efficiency, a structural advantage over autologous approaches that require individualized production and cannot easily be standardized across large patient populations. #6. Bullish Technicals At close on Tuesday, Barchart was reporting at least 8 triggered technical indicators across terms. Furthermore, one of those eight that were triggered was the website's composite "Trend Seeker" indicator. #7. Deep Advisory Bench The scientific advisory board assembled around NCEL includes Dr. Julien Boisdron (CMO at a major Swiss multinational pharma, 20+ years in diabetes care); Prof. Jeremy Shefner, MD, PhD (CMO at Barrow Neurological Institute, co-founder of NEALS ALS consortium, 200+ peer-reviewed papers); and Prof. Tamir Ben-Hur, MD, PhD (neuroimmunology expert at Hadassah and Hebrew University). We Will Have All Eyes On NewcelX (Nasdaq: NCEL) Wednesday Morning. NewcelX Ltd. (Nasdaq: NCEL) is navigating the most consequential stretch of its existence. The merger that created it is less than a year old. Its lead program has just completed its Pre-IND submission to the FDA. A Type B meeting with regulators was scheduled for the end of June. The scientific advisory board has been built with purpose. The manufacturing partner is in place. The immune protection collaborator has clinical data from over 100 transplant recipients. What markets are watching is whether the company can convert that groundwork into a cleared IND and a path to First-In-Human data. The disease it is targeting affects 9.5Mn people globally. The current standard of care is a lifetime of daily management. The approach NewcelX is advancing goes further, it is aimed at the underlying biology. We're kicking off coverage on NewcelX Ltd. (Nasdaq: NCEL). Be on the lookout for updates coming soon. Talk again shortly. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. NewcelX Ltd (NCEL:US) previously changed their company name and symbols from NLS Pharmaceutics AG (NLSP:US) Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 06/30/2026 and ending on 07/01/2026 to publicly disseminate information about (NCEL:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC twenty thousand USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid fifty two thousand five hundred USD ("Funds"). These Funds were part of the twenty seven thousand five hundred USD funds that TD Media LLC received from a third party named LFG Equities Corp. who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (NCEL:US). Please see important disclosure information here: https://fierceinvestor.com/disclosure/ncel-kghgw/#details

Fierce Investor | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice